Skip to content

Tranexamic acid during excisional burn surgery

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2024-513573-49-00
Enrollment
95
Registered
2024-04-26
Start date
2021-11-03
Completion date
2025-11-26
Last updated
2024-04-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Burn injury

Brief summary

The main study endpoints are the volume of blood loss and the extend of fibrinolysis.

Detailed description

Blood transfusion requirements: - Number of blood product transfused Hospital Mortality Length of stay Operation success: - Success of skin graft (percentage successful take) Cardiopulmonary complication (i.e. arterial embolism) Neurologic complications (i.e. stroke, conclusion) Strength of the blood cloth and fibrin-structures

Interventions

DRUGCyklokapron 100 mg/ml
DRUGoplossing voor injectie/infusie.
DRUG9%

Sponsors

Maasstad Ziekenhuis Stichting
Lead SponsorOTHER

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Design outcomes

Primary

MeasureTime frame
The main study endpoints are the volume of blood loss and the extend of fibrinolysis.

Secondary

MeasureTime frame
Blood transfusion requirements: - Number of blood product transfused Hospital Mortality Length of stay Operation success: - Success of skin graft (percentage successful take) Cardiopulmonary complication (i.e. arterial embolism) Neurologic complications (i.e. stroke, conclusion) Strength of the blood cloth and fibrin-structures

Countries

Netherlands

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026